Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

137
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
137
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

145
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
145
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

188
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
188

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apoptotic Colitis in a Liver Transplant Recipient: A Case of Solid Organ Transplant-Associated Graft-Versus-Host Disease.

Cureus·2026
Same author

Submucosal-Predominant (Inverted-Type) Pyloric Gland Adenoma of the Duodenum Mimicking Malignancy.

ACG case reports journal·2026
Same author

Gastrointestinal Tract Endometriosis: Clinicopathologic Features and Anatomic Distribution in an Institutional Cohort.

Human pathology·2026
Same author

Thermal resection-margin artifact mimicking goblet cell adenocarcinoma in appendectomy specimens: clinicopathologic correlation with appendiceal stump technique.

Human pathology·2026
Same author

An Unusual Pattern of Hepatic Involvement in Plasma Cell Leukemia.

Cureus·2026
Same author

From Palpitations to Prevention: Timely Recognition of Biventricular ACM Preventing Sudden Cardiac Death.

Case reports in cardiology·2026

Related Experiment Video

Updated: Jun 8, 2025

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
07:05

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy

Published on: September 27, 2024

408

Tirzepatide-Associated Colonic Ischemia.

David Bayless1, Jasraj Singh1, Byoung Uk Park1

  • 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

ACG Case Reports Journal
|November 7, 2024
PubMed
Summary
This summary is machine-generated.

Tirzepatide, a GLP-1/GIP agonist used for weight loss and diabetes, may be linked to colonic ischemia. This case report suggests a potential risk and highlights factors to consider before prescribing this popular medication.

Keywords:
colonic ischemiaglucagon-like peptide-1 receptor agoniststirzepatide

More Related Videos

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

4.2K
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

32.1K

Related Experiment Videos

Last Updated: Jun 8, 2025

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
07:05

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy

Published on: September 27, 2024

408
Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

4.2K
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

32.1K

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, such as tirzepatide, are increasingly prescribed for weight loss and type 2 diabetes management.
  • Common side effects include gastrointestinal issues like nausea, vomiting, and constipation.

Observation:

  • A case of colonic ischemia was observed in a 62-year-old female patient undergoing tirzepatide treatment for weight loss.
  • The ischemic event occurred during the course of tirzepatide therapy.

Findings:

  • This case suggests a potential association between GLP-1/GIP agonist therapy and the development of colonic ischemia.
  • The findings highlight the need to consider this rare but serious adverse event in patients using tirzepatide.

Implications:

  • Healthcare providers should be aware of the potential risk of colonic ischemia with tirzepatide use.
  • Identifying and managing risk factors is crucial for patient safety when prescribing GLP-1/GIP agonists.